Lily Allen is sharing painful moments from her past with the help of friend Dakota Johnson. During Allen's performance of "Madeline" — a song that is believed to reference a mistress who allegedly had ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Eli Lilly and Co. is planning to build a new $6 billion manufacturing facility in Huntsville, Alabama. (Rendering courtesy of Eli Lilly and Co.) Eli Lilly and Co. on Tuesday announced plans to spend ...

Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ...

Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY) posted 54% revenue growth driven by ...

The Lilly Endowment announced it will distribute 45 large-scale grants to theological schools across the U.S. and Canada, including directing about $60 million to several Catholic institutions. The ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...